JP2020509016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509016A5 JP2020509016A5 JP2019546924A JP2019546924A JP2020509016A5 JP 2020509016 A5 JP2020509016 A5 JP 2020509016A5 JP 2019546924 A JP2019546924 A JP 2019546924A JP 2019546924 A JP2019546924 A JP 2019546924A JP 2020509016 A5 JP2020509016 A5 JP 2020509016A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide sequence
- composition according
- rna
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037923A JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
| JP2022203863A JP7461449B2 (ja) | 2017-02-28 | 2022-12-21 | 治療用ｒｎａ |
| JP2024045866A JP2024073650A (ja) | 2017-02-28 | 2024-03-22 | 治療用ｒｎａ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464981P | 2017-02-28 | 2017-02-28 | |
| US62/464,981 | 2017-02-28 | ||
| EP17306089 | 2017-08-23 | ||
| EP17306089.8 | 2017-08-23 | ||
| US201762597527P | 2017-12-12 | 2017-12-12 | |
| US62/597,527 | 2017-12-12 | ||
| PCT/US2018/019878 WO2018160540A1 (en) | 2017-02-28 | 2018-02-27 | Therapeutic rna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037923A Division JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509016A JP2020509016A (ja) | 2020-03-26 |
| JP2020509016A5 true JP2020509016A5 (https=) | 2021-07-29 |
| JP6949131B2 JP6949131B2 (ja) | 2021-10-13 |
Family
ID=61569463
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546924A Active JP6949131B2 (ja) | 2017-02-28 | 2018-02-27 | 治療用ｒｎａ |
| JP2021037923A Active JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
| JP2022203863A Active JP7461449B2 (ja) | 2017-02-28 | 2022-12-21 | 治療用ｒｎａ |
| JP2024045866A Pending JP2024073650A (ja) | 2017-02-28 | 2024-03-22 | 治療用ｒｎａ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037923A Active JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
| JP2022203863A Active JP7461449B2 (ja) | 2017-02-28 | 2022-12-21 | 治療用ｒｎａ |
| JP2024045866A Pending JP2024073650A (ja) | 2017-02-28 | 2024-03-22 | 治療用ｒｎａ |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20200147176A1 (https=) |
| EP (1) | EP3589308A1 (https=) |
| JP (4) | JP6949131B2 (https=) |
| KR (2) | KR102700956B1 (https=) |
| CN (1) | CN110337305A (https=) |
| AU (1) | AU2018229278A1 (https=) |
| BR (1) | BR112019017743A2 (https=) |
| CA (1) | CA3054733A1 (https=) |
| CL (1) | CL2019002461A1 (https=) |
| CO (1) | CO2019010355A2 (https=) |
| CR (1) | CR20190444A (https=) |
| EC (1) | ECSP19070336A (https=) |
| IL (1) | IL268894A (https=) |
| MA (1) | MA47680A (https=) |
| MX (1) | MX2019010269A (https=) |
| PE (1) | PE20200735A1 (https=) |
| PH (1) | PH12019501959A1 (https=) |
| SG (1) | SG11201907846VA (https=) |
| TW (2) | TW202428301A (https=) |
| UY (1) | UY37621A (https=) |
| WO (1) | WO2018160540A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428301A (zh) * | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| WO2020041655A1 (en) * | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| AU2020208193A1 (en) * | 2019-01-14 | 2021-07-29 | BioNTech SE | Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine |
| WO2020154187A1 (en) * | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
| AU2020210614A1 (en) * | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
| CN113710267B (zh) * | 2019-03-12 | 2025-05-09 | 生物技术公司 | 用于前列腺癌的治疗性rna |
| WO2020200481A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
| WO2021072172A1 (en) * | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| US20220380720A1 (en) * | 2019-11-12 | 2022-12-01 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| MX2022009391A (es) * | 2020-01-31 | 2022-09-26 | Genentech Inc | Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn. |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| EP4185274A1 (en) * | 2020-07-24 | 2023-05-31 | Strand Therapeutics Inc. | Lipidnanoparticle comprising modified nucleotides |
| CA3198727A1 (en) * | 2020-10-20 | 2022-04-28 | St Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
| WO2022096582A1 (en) * | 2020-11-04 | 2022-05-12 | Ethris Gmbh | Use of ifn-lambda mrna for treating viral infections |
| TW202245808A (zh) * | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| AR124599A1 (es) | 2021-01-08 | 2023-04-12 | Strand Therapeutics Inc | Constructos de expresión y usos de estos |
| US20240102065A1 (en) * | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CN115702940A (zh) * | 2021-08-05 | 2023-02-17 | 苏州科锐迈德生物医药科技有限公司 | 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用 |
| CN116829578B (zh) * | 2021-10-08 | 2025-03-21 | 苏州艾博生物科技有限公司 | 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN116179549A (zh) | 2021-12-08 | 2023-05-30 | 南京吉迈生物技术有限公司 | 通过5’utr序列变体修饰基因转录和翻译效率 |
| CN119317430A (zh) | 2022-04-26 | 2025-01-14 | 斯特兰德生物科技公司 | 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途 |
| CN115960906A (zh) * | 2022-05-07 | 2023-04-14 | 苏州科锐迈德生物医药科技有限公司 | 用于抗肿瘤免疫治疗的rna组合物、rna制剂及用途 |
| TW202400784A (zh) | 2022-05-13 | 2024-01-01 | 大陸商上海瑞宏迪醫藥有限公司 | 包含utr的核酸構建體及其應用 |
| CN117327709A (zh) * | 2022-06-24 | 2024-01-02 | 深圳瑞吉生物科技有限公司 | 用于实体肿瘤的治疗性mRNA及其应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| WO2024074211A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024074634A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| KR20260003656A (ko) | 2023-04-12 | 2026-01-07 | 스트랜드 세러퓨틱스 인코포레이티드 | 합성 회로 및 이의 용도 |
| CN121909034A (zh) | 2023-07-24 | 2026-04-21 | 斯特兰德生物科技公司 | 用于产生用于体外细胞疗法的工程化免疫细胞的基于rna的合成回路 |
| AU2024299882A1 (en) | 2023-07-25 | 2026-01-08 | Strand Therapeutics Inc. | Polynucleotides comprising a micro rna detargeting sensor and uses thereof |
| KR102935773B1 (ko) * | 2023-09-01 | 2026-03-09 | 한양대학교 산학협력단 | 증강된 유전자 발현을 위한 5‘ 비번역 영역을 포함하는 뉴클레오타이드를 포함하는 조성물 및 방법 |
| WO2025217591A1 (en) | 2024-04-12 | 2025-10-16 | Strand Therapeutics Inc. | Human-derived synthetic regulators and uses thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP1442750B1 (en) | 1997-11-20 | 2012-08-01 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
| ATE305801T1 (de) | 2000-01-20 | 2005-10-15 | Univ Zuerich Inst Fuer Medizin | Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle |
| ES2164011B1 (es) | 2000-02-25 | 2003-05-16 | Inst Cientifico Tecnol Navarra | Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos. |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| WO2003059381A2 (en) | 2002-01-18 | 2003-07-24 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8476419B2 (en) | 2007-09-14 | 2013-07-02 | Vrije Universiteit Brussel | Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US20130108663A1 (en) | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| WO2009114816A2 (en) | 2008-03-14 | 2009-09-17 | The Board Of Trustees Of The University Of Illinois | Therapeutic cancer antigens |
| WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US8808982B2 (en) | 2009-12-07 | 2014-08-19 | Cellscript, Llc | Compositions and methods for reprogramming eukaryotic cells |
| KR20130010121A (ko) | 2010-03-23 | 2013-01-25 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| MX342608B (es) | 2010-07-06 | 2016-10-06 | Novartis Ag * | Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion. |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| EP2766035B1 (en) | 2011-10-11 | 2018-03-28 | Universität Zürich Prorektorat MNW | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| RS57739B1 (sr) * | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| RU2016109938A (ru) | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
| MY174677A (en) | 2013-08-21 | 2020-05-06 | Curevac Ag | Composition and vaccine for treating lung cancer |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JP2017501712A (ja) * | 2013-12-18 | 2017-01-19 | イントレキソン コーポレーション | 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用 |
| GB2517521B (en) | 2013-12-19 | 2015-07-29 | Anacail Ltd | Drain decontamination system |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CN105031630A (zh) * | 2014-04-28 | 2015-11-11 | 四川大学 | 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法 |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| CN108064176A (zh) * | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017027843A1 (en) * | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| EP3402498A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| CN109715205A (zh) | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | 用于癌症治疗的rna |
| TW202428301A (zh) * | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| WO2020041655A1 (en) | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| WO2020154187A1 (en) | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
| AU2020210614A1 (en) | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
-
2018
- 2018-02-27 TW TW112135033A patent/TW202428301A/zh unknown
- 2018-02-27 CR CR20190444A patent/CR20190444A/es unknown
- 2018-02-27 UY UY0001037621A patent/UY37621A/es not_active Application Discontinuation
- 2018-02-27 PE PE2019001764A patent/PE20200735A1/es unknown
- 2018-02-27 CN CN201880013857.3A patent/CN110337305A/zh active Pending
- 2018-02-27 BR BR112019017743A patent/BR112019017743A2/pt not_active IP Right Cessation
- 2018-02-27 KR KR1020197028213A patent/KR102700956B1/ko active Active
- 2018-02-27 KR KR1020247028726A patent/KR20240144261A/ko active Pending
- 2018-02-27 AU AU2018229278A patent/AU2018229278A1/en not_active Abandoned
- 2018-02-27 WO PCT/US2018/019878 patent/WO2018160540A1/en not_active Ceased
- 2018-02-27 SG SG11201907846VA patent/SG11201907846VA/en unknown
- 2018-02-27 MA MA047680A patent/MA47680A/fr unknown
- 2018-02-27 JP JP2019546924A patent/JP6949131B2/ja active Active
- 2018-02-27 CA CA3054733A patent/CA3054733A1/en active Pending
- 2018-02-27 MX MX2019010269A patent/MX2019010269A/es unknown
- 2018-02-27 EP EP18709243.2A patent/EP3589308A1/en active Pending
- 2018-02-27 TW TW107106479A patent/TW201842921A/zh unknown
-
2019
- 2019-08-25 IL IL26889419A patent/IL268894A/en unknown
- 2019-08-26 CL CL2019002461A patent/CL2019002461A1/es unknown
- 2019-08-27 US US16/552,248 patent/US20200147176A1/en not_active Abandoned
- 2019-08-27 PH PH12019501959A patent/PH12019501959A1/en unknown
- 2019-09-25 CO CONC2019/0010355A patent/CO2019010355A2/es unknown
- 2019-09-27 EC ECSENADI201970336A patent/ECSP19070336A/es unknown
-
2021
- 2021-03-10 JP JP2021037923A patent/JP7201725B2/ja active Active
- 2021-04-30 US US17/245,605 patent/US11865159B2/en active Active
-
2022
- 2022-12-21 JP JP2022203863A patent/JP7461449B2/ja active Active
-
2023
- 2023-11-21 US US18/516,006 patent/US20240173382A1/en active Pending
-
2024
- 2024-03-22 JP JP2024045866A patent/JP2024073650A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509016A5 (https=) | ||
| AU2017374044B2 (en) | Modified guide RNAs | |
| Green et al. | Sequence analysis of the gene encoding the serotype-specific glycoprotein (VP7) of two new human rotavirus serotypes | |
| JP2023513502A5 (https=) | ||
| EP4527459A3 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
| ZA202003137B (en) | Nucleic acid, composition and conjugate containing same, and preparation method and use | |
| JP2014525461A5 (https=) | ||
| JP2020022459A5 (https=) | ||
| US20170326225A1 (en) | Ebolavirus and marburgvirus vaccines | |
| JP2013535212A5 (https=) | ||
| JP2015128433A5 (https=) | ||
| WO2000061770A3 (en) | Enhancement of the immune response for vaccine and gene therapy applications | |
| RU2016109938A (ru) | Композиция и вакцина для лечения рака предстательной железы | |
| JP2018512110A5 (https=) | ||
| JP2015513897A5 (https=) | ||
| JP2017070307A5 (https=) | ||
| JP2014527401A5 (https=) | ||
| JP2018512041A5 (https=) | ||
| JP2005500025A5 (https=) | ||
| JP2009544281A5 (https=) | ||
| EP2527445A3 (en) | Treatment and prevention of influenza | |
| JP2011524745A5 (https=) | ||
| WO2002044390A3 (en) | Floral development genes | |
| NZ604094A (en) | Double stranded rna compounds to rhoa and use thereof | |
| WO2004018630A3 (en) | Recombinant double-stranded rna phages and uses thereof |